Payment overview · 2025
General Payments
$764.32
44 reported records · 16 companies
Healthcare provider profile · identity verified
Patricia M. Ryan, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MECHANICSVILLE, VA · NPI 1790740033
Verified facts
What the public records show
CMS Open Payments records show Patricia M. Ryan, M.D. received $764.32 in general payments during 2025 across 44 reported records.
ABBVIE INC. accounted for 27.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $209.30 | 27.4% | 17 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $200.39 | 26.2% | 12 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $70.02 | 9.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $37.24 | 4.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $35.40 | 4.6% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $27.65 | 3.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $24.43 | 3.2% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $22.23 | 2.9% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $19.76 | 2.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.56 | 2.6% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $19.08 | 2.5% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.82 | 2.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.24 | 2.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.81 | 1.9% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $14.80 | 1.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.59 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $764.32 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $165.14 | 13 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $165.14 | 13 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $81.25 | 6 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $81.25 | 6 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $81.25 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $78.30 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $78.30 | 4 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $70.02 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $44.16 | 4 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $40.84 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $37.24 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $35.40 | 2 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $27.65 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $27.65 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $22.23 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $19.76 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.56 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| AZMIRO Normalized: azmiro |
Drug | Azurity Pharmaceuticals, Inc. | $18.82 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $17.24 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.81 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $14.80 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.59 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 140 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
47 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
140 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
57 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 595 | 165 |
| Amlodipine Besylate | Amlodipine Besylate | 524 | 147 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 413 | 117 |
| Losartan Potassium | Losartan Potassium | 319 | 89 |
| Levothyroxine Sodium | Levothyroxine Sodium | 315 | 80 |
| Hydrochlorothiazide | Hydrochlorothiazide | 247 | 67 |
| Lisinopril | Lisinopril | 243 | 69 |
| Sertraline Hcl | Sertraline Hcl | 178 | 47 |
| Metformin Hcl | Metformin Hcl | 173 | 44 |
| Omeprazole | Omeprazole | 167 | 54 |
| Valsartan | Valsartan | 157 | 44 |
| Simvastatin | Simvastatin | 148 | 35 |
| Jardiance | Empagliflozin | 140 | 29 |
| Atenolol | Atenolol | 135 | 31 |
| Metformin Hcl Er | Metformin Hcl | 124 | 38 |
| Gabapentin | Gabapentin | 120 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 119 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 118 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 107 | 29 |
| Potassium Chloride | Potassium Chloride | 104 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 97 | 30 |
| Alendronate Sodium | Alendronate Sodium | 91 | 27 |
| Furosemide | Furosemide | 89 | 24 |
| Montelukast Sodium | Montelukast Sodium | 89 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 88 | 23 |
| Trazodone Hcl | Trazodone Hcl | 88 | 21 |
| Ezetimibe | Ezetimibe | 86 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 72 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 60 | 20 |
| Bupropion Xl | Bupropion Hcl | 59 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | 15 |
| Ozempic | Semaglutide | 57 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | 14 |
| Methylprednisolone | Methylprednisolone | 55 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 54 | 24 |
| Allopurinol | Allopurinol | 53 | 18 |
| Azithromycin | Azithromycin | 53 | 49 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 49 | 13 |
| Synthroid | Levothyroxine Sodium | 47 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 44 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 15 |
| Trulicity | Dulaglutide | 42 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 39 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 39 | 18 |
| Glipizide Er | Glipizide | 38 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | suppressed |
| Carvedilol | Carvedilol | 35 | 12 |
| Famotidine | Famotidine | 35 | 13 |
| Lorazepam | Lorazepam | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 30 |
| Lovastatin | Lovastatin | 34 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 31 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 30 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Celecoxib | Celecoxib | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Estradiol | Estradiol | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Rybelsus | Semaglutide | 26 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 15 |
| Meloxicam | Meloxicam | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Nystatin | Nystatin | 25 | suppressed |
| Eliquis | Apixaban | 24 | suppressed |
| Glimepiride | Glimepiride | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Cephalexin | Cephalexin | 23 | 19 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 21 |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Klor-Con M20 | Potassium Chloride | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 14 |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 15 |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 14 |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Cefdinir | Cefdinir | 14 | 13 |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Prednisone | Prednisone | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Risedronate Sodium | Risedronate Sodium | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $764.32 · 44 records | ABBVIE INC. | ABRYSVO, ACCRUFER, AREXVY, AZMIRO, COMIRNATY, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, Fluad, Flucelvax, GEMTESA, GVOKE HYPOPEN, JARDIANCE, NURTEC ODT, PREVNAR 20, QULIPTA, SHINGRIX, TRINTELLIX, UBRELVY, UNITHROID, VRAYLAR, VYNDAQEL, WATCHMAN FLX, XIFAXAN, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error